RxDoctor Payments DataLook up a doctor →

Sanford Chen, MD

Ophthalmology · Santa Ana, CANPI 1427051994

Payments from drug & device makers

$2,306,680in general payments, 2019–2025

Across 852 payments — averaging $2707.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.7M
  • Novartis$247K
  • Ocular Therapeutix, Inc.$85K
  • Astellas Pharma Global Development$48K
  • Regeneron$46K
  • Amgen$46K
  • plus $137K from 33 others
$6,893in research payments, 2019–2025

Across 11 payments — averaging $626.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$4K
  • Regeneron$3K

What the payments were for

  • Consulting fees$34,96127%
  • Speaking & faculty fees$53,17341%
  • Travel & lodging$13,18710%
  • Food & beverage$27,11721%
  • Education$410%
  • Entertainment$2630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,306,680 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$3,980,155
Medicare patients
890
Services billed
192,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate14$9,096
ProlensaBromfenac Sodium26$8,917
Prednisolone Acetate85$2,934
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$1,652
Difluprednate12$964
Atropine Sulfate16$570
MoxifloxacinMoxifloxacin Hcl16$325
Latanoprost26$242
Ketorolac Tromethamine14$199
Ofloxacin13$148
Ciprofloxacin Hcl14$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$390$9,09614 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$76$8,91726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →